Fig. 2From: Naringenin alters the pharmacokinetics of ranolazine in part through the inhibition of cytochrome P450 (3A4) and P-glycoproteinRanolazine plasma concentration levels in SDS and MDS with and without naringenin (n = 6). SDS single-dose study, MDS multi-dose studyBack to article page